This cohort study compares the risk of glycemic outcomes and adverse events among insulin-treated adults with diabetes and Alzheimer disease and related dementias who use either continuous glucose monitoring (CGM) or self-monitoring of blood glucose. The gene discussed is INS; the disease is early-onset autosomal dominant Alzheimer disease.